Tarsus Pharmaceuticals, Inc. TARS Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s interest expense?
- Tarsus Pharmaceuticals, Inc. (TARS) reported interest expense of $2.13M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s interest expense changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s interest expense decreased by 3.8% year-over-year, from $2.21M to $2.13M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s interest expense?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s interest expense has grown at a 386.1% compound annual growth rate (CAGR), from $16K to $8.94M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.